Luminex in Alpha Stage for New MDx Platform; Ups R&D Spending to Prep for Market | GenomeWeb

Luminex CEO Patrick Balthrop said this week that the company is "well into the alpha stage" of development for its high-volume, low-multiplex, cartridge-based clinical diagnostic system, dubbed Project Aries.

As such, Luminex's R&D spend increased by approximately 26 percent in the first quarter, a trend that it sees continuing over the next several quarters — though at a slightly slower pace — as it prepares the sample-to-answer testing platform for beta testing and possible commercialization next year, Balthrop said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.